We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

68 hedge funds and large institutions have $34.4M invested in Matinas BioPharma in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 5 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 5

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

6% more funds holding

Funds holding: 64 → 68 (+4)

0.22% more ownership

Funds ownership: 0.37% → 0.58% (+0.22%)

49% less capital invested

Capital invested by funds: $67.4M → $34.4M (-$33M)

Holders
68
Holders Change
+4
Holders Change %
+6.25%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
27
Reduced
5
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$13.6M
2
Victory Capital Management
Victory Capital Management
Texas
+$7.75M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.74M
4
BC
Boxer Capital
California
+$1.56M
5
BBA
Baker Bros. Advisors
New York
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$454K
2
OAM
Oxford Asset Management
United Kingdom
-$251K
3
ECM
ExodusPoint Capital Management
New York
-$180K
4
SG Americas Securities
SG Americas Securities
New York
-$101K
5
IWAG
Integer Wealth Advisors Group
Georgia
-$82K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Boxer Capital
California
$6.89M +$1.56M +25,807 +13%
VC
2
Vivo Capital
California
$6.77M +$13.6M +225,586 New
Victory Capital Management
3
Victory Capital Management
Texas
$4.67M +$7.75M +128,356 +469%
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.54M +$2.74M +45,315 +43%
BBA
5
Baker Bros. Advisors
New York
$2.25M +$1.35M +22,437 +43%
BlackRock
6
BlackRock
New York
$1.31M +$169K +2,801 +7%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$775K +$853K +14,122 +121%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$647K +$254K +4,212 +24%
Renaissance Technologies
9
Renaissance Technologies
New York
$615K +$877K +14,527 +244%
Millennium Management
10
Millennium Management
New York
$575K +$1.04M +17,284 +916%
RJFSA
11
Raymond James Financial Services Advisors
Florida
$481K +$8.7K +144 +0.9%
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$474K +$7.13K +118 +0.8%
Morgan Stanley
13
Morgan Stanley
New York
$429K +$842K +13,948 +4,031%
Two Sigma Investments
14
Two Sigma Investments
New York
$404K +$813K +13,465 New
DA
15
DCF Advisers
Connecticut
$372K +$418K +6,920 +126%
SCA
16
STALEY CAPITAL ADVISERS
Pennsylvania
$300K – – –
Wells Fargo
17
Wells Fargo
California
$295K +$145K +2,395 +32%
WIC
18
Water Island Capital
New York
$285K +$574K +9,513 New
BCM
19
Bridgeway Capital Management
Texas
$204K – – –
ECM
20
ExodusPoint Capital Management
New York
$195K -$180K -2,986 -32%
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$182K +$26.9K +446 +7%
Northern Trust
22
Northern Trust
Illinois
$180K +$74.4K +1,233 +26%
Goldman Sachs
23
Goldman Sachs
New York
$146K +$188K +3,119 +179%
Jane Street
24
Jane Street
New York
$130K +$262K +4,345 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$120K +$54.3K +900 +29%
1
2 3

MTNB Hedge Fund Activity: Q1 2020 in Review

68 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2020, worth a combined $34.4M — down 49% from $67.4M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MTNB positions and 8 closed out — a net gain of 6 holders — while 27 added to existing stakes and 5 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $13.6M. The largest seller was CIBC Private Wealth Group, exiting entirely with an estimated $454K sold.

  • 68 institutional investors held Matinas BioPharma (MTNB) as of Q1 2020, up from 64 in Q4 2019.
  • Funds reported $34.4M of Matinas BioPharma stock for Q1 2020, down 49% quarter-over-quarter.
  • 14 funds opened new Matinas BioPharma positions in Q1 2020 and 8 closed out, a net change of +6 holders.
  • The largest Matinas BioPharma buyer in Q1 2020 was Vivo Capital, an estimated $13.6M added.
  • The largest Matinas BioPharma seller in Q1 2020 was CIBC Private Wealth Group, an estimated $454K sold.

Based on aggregated 13F filings for Q1 2020.